课题基金 / 基金详情

New Selective PET Imaging Antagonist for the Sphingosine-1-Phosphate Receptors: Novel Biomarkers for Multiple Sclerosis Drug Discovery

New Selective PET Imaging Antagonist for the Sphingosine-1-Phosphate Receptors: Novel Biomarkers for Multiple Sclerosis Drug Discovery
1-磷酸鞘氨醇受体的新型选择性 PET 成像拮抗剂:用于多发性硬化症药物发现的新型生物标志物
批准号:
2749011
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
该博士研究生的重点是开发一种潜在的PET显像剂,作为鞘氨醇-1受体的选择性拮抗剂。最近在文献报道中发现了一类对S1P5具有选择性和拮抗活性的化合物。以这些结构为起点,我们将设计和合成一个小的类似物库,其中包含一个氟原子,并且可以进行后期放射性标记。在对这些新化合物的亲和力进行生物学测试后,将研究其放射性标记方法。最终,该研究项目将为多发性硬化症治疗提供具有几种潜在临床应用的新成像工具,包括疾病进展评估、治疗反应和未来药物发现项目中的应用。
英文摘要
The focus of this PhD studentship is to develop a potential PET imaging agent that would act as a selective antagonist for the sphingosine-1-receptor. Recent work reported in the literature has identified a class of compounds that show selectivity and antagonist activity for S1P5. Using these structures as a starting point, we will design and synthesise a small library of analogues which incorporate a fluorine atom and that can undergo late-stage radiolabelling. Following biological testing of these novel compounds for affinity, methods for their radiolabelling will then be investigated. Ultimately, this programme of research will deliver new imaging tools with several potential clinical applications for multiple sclerosis treatment, including evaluation of disease progression, response to therapy and application in future drug discovery programmes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金